Cargando…

Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus

Type I interferon (IFN) pathways are significant in SLE pathogenesis. Less is known about the utility of measuring markers of IFN activity in patients, or whether patient subsets with different profiles exist. We explored the longitudinal associations of IFN-induced chemokines with disease activity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Connelly, K. L., Kandane-Rathnayake, R., Huq, M., Hoi, A., Nikpour, M., Morand, E. F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818532/ https://www.ncbi.nlm.nih.gov/pubmed/29459655 http://dx.doi.org/10.1038/s41598-018-20203-9

Ejemplares similares

Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus
por: Connelly, K. L., et al.
Publicado: (2016)

Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis
por: Northcott, Melissa, et al.
Publicado: (2022)

Clinical associations of cognitive dysfunction in systemic lupus erythematosus
por: Raghunath, Sudha, et al.
Publicado: (2023)

Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus
por: Godsell, Jack, et al.
Publicado: (2016)

Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study
por: Louthrenoo, Worawit, et al.
Publicado: (2020)

Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2018)

Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2020)

Analysis of serum B cell‐activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2019)

Fibromyalgia, mood disorders, cognitive test results, cognitive symptoms and quality of life in systemic lupus erythematosus
por: Raghunath, Sudha, et al.
Publicado: (2022)

Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus
por: Mende, Rachel, et al.
Publicado: (2018)

Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study
por: Kandane-Rathnayake, Rangi, et al.
Publicado: (2021)

Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort
por: Yap, K S, et al.
Publicado: (2015)

Independent association of glucocorticoids with damage accrual in SLE
por: Apostolopoulos, Diane, et al.
Publicado: (2016)

A potential association between IL‐3 and type I and III interferons in systemic lupus erythematosus
por: Oon, Shereen, et al.
Publicado: (2019)

Novel Methods of Incorporating Time in Longitudinal Multivariate Analysis Reveals Hidden Associations With Disease Activity in Systemic Lupus Erythematosus
por: Nim, Hieu T., et al.
Publicado: (2019)

Elevated Serum Levels of Interferon-Regulated Chemokines Are Biomarkers for Active Human Systemic Lupus Erythematosus
por: Bauer, Jason W, et al.
Publicado: (2006)

High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus
por: Koelmeyer, Rachel, et al.
Publicado: (2020)

Association of clinic setting with quality indicator performance in systemic lupus erythematosus: a cross-sectional study
por: Sreedharan, Sidha, et al.
Publicado: (2022)

Systemic lupus erythematosus and the type I interferon system
por: Rönnblom, Lars, et al.
Publicado: (2003)

Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients
por: Fu, Qiong, et al.
Publicado: (2008)

Interferon Alpha in Systemic Lupus Erythematosus
por: Niewold, Timothy B., et al.
Publicado: (2010)

Cytokines and Chemokines in Neuropsychiatric Syndromes of Systemic Lupus Erythematosus
por: Okamoto, Hiroshi, et al.
Publicado: (2010)

Clinical associations of serum interleukin-17 in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2013)

Editorial: Focus on Systemic Lupus Erythematosus
por: Harris, James, et al.
Publicado: (2016)

Interferon targeted therapies in systemic lupus erythematosus
por: Misra, Durga Prasanna, et al.
Publicado: (2017)

Interferon-induced versus chemokine transcripts as lupus biomarkers
por: Crow, Mary K, et al.
Publicado: (2008)

Type I Interferon Predicts an Alternate Immune System Phenotype in Systemic Lupus Erythematosus
por: Thanarajasingam, Uma, et al.
Publicado: (2019)

‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study
por: Kandane-Rathnayake, Rangi, et al.
Publicado: (2022)

Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood
por: Bennett, Lynda, et al.
Publicado: (2003)

A new tool for detection of type I interferon activation in systemic lupus erythematosus
por: Kirou, Kyriakos A, et al.
Publicado: (2010)

Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus
por: Smith, Michael A., et al.
Publicado: (2020)

Immunosuppressant exposure confounds gene expression analysis in systemic lupus erythematosus
por: Northcott, Melissa, et al.
Publicado: (2022)

Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity
por: Wu, Qian, et al.
Publicado: (2011)

Nucleic Acid Sensors and Type I Interferon Production in Systemic Lupus Erythematosus
por: Shrivastav, Meena, et al.
Publicado: (2013)

Interferon Regulatory Factor 5 in the Pathogenesis of Systemic Lupus Erythematosus
por: Cham, Candace M., et al.
Publicado: (2012)

Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus
por: Emamikia, Sharzad, et al.
Publicado: (2022)

Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study
por: Nikpour, Mandana, et al.
Publicado: (2010)

Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study
por: Golder, Vera, et al.
Publicado: (2017)

Activation of Type I Interferon Pathway in Systemic Lupus Erythematosus: Association with Distinct Clinical Phenotypes
por: Karageorgas, Theophanis P., et al.
Publicado: (2011)

Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus
por: Tydén, Helena, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_q5v5kn9irubprkahi1osbdi5n0